|
1
|
Hinestrosa MC, Dickersin K, Klein P, Mayer
M, Noss K, Slamon D, Sledge G and Visco FM: Shaping the future of
biomarker research in breast cancer to ensure clinical relevance.
Nat Rev Cancer. 7:309–315. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu Y, Li H, Feng J, Cui X, Huang W, Li Y,
Su F, Liu Q, Zhu J, Lv X, et al: Lin28 induces
epithelial-to-mesenchymal transition and stemness via
downregulation of let-7a in breast cancer cells. PLoS One.
8:e830832013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dworkin AM, Huang TH and Toland AE:
Epigenetic alterations in the breast: Implications for breast
cancer detection, prognosis and treatment. Semin Cancer Biol.
19:165–171. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Feng L, Xie X, Ding Q, Luo X, He J, Fan F,
Liu W, Wang Z and Chen Y: Spatial regulation of Raf kinase
signaling by RKTG. Proc Natl Acad Sci USA. 104:14348–14353. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luo X, Feng L, Jiang X, Xiao F, Wang Z,
Feng GS and Chen Y: Characterization of the topology and functional
domains of RKTG. Biochem J. 414:399–406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xie X, Zhang Y, Jiang Y, Liu W, Ma H, Wang
Z and Chen Y: Suppressive function of RKTG on chemical
carcinogen-induced skin carcinogenesis in mouse. Carcinogenesis.
29:1632–1638. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Y, Jiang X, Qin X, Ye D, Yi Z, Liu
M, Bai OW, Xie X, Wang Z, et al: RKTG inhibits angiogenesis by
suppressing MAPK-mediated autocrine VEGF signaling and is
down-regulated in clear-cell renal cell carcinoma. Oncogene.
29:5404–5415. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fan F, Feng L, He J, Wang X, Jiang X,
Zhang Y, Wang Z and Chen Y: RKTG sequesters B-Raf to the Golgi
apparatus and inhibits the proliferation and tumorigenicity of
human malignant melanoma cells. Carcinogenesis. 29:1157–1163. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang X, Li X, Fan F, Jiao S, Wang L, Zhu
L, Pan Y, Wu G, Ling ZQ, Fang J, et al: PAQR3 plays a suppressive
role in the tumorigenesis of colorectal cancers. Carcinogenesis.
33:2228–2235. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ling ZQ, Guo W, Lu XX, Zhu X, Hong LL,
Wang Z, Wang Z and Chen Y: A Golgi-specific protein PAQR3 is
closely associated with the progression, metastasis and prognosis
of human gastric cancers. Ann Oncol. 25:1363–1372. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma Z, Wang Y, Piao T, Li Z, Zhang H, Liu Z
and Liu J: The tumor suppressor role of PAQR3 in osteosarcoma.
Tumour Biol. 36:3319–3324. 2015. View Article : Google Scholar
|
|
12
|
Tang YT, Hu T, Arterburn M, Boyle B,
Bright JM, Emtage PC and Funk WD: PAQR proteins: A novel membrane
receptor family defined by an ancient 7-transmembrane pass motif. J
Mol Evol. 61:372–380. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Wang X, Li Z, Xia T, Zhu L, Liu B,
Zhang Y, Xiao F, Pan Y, Liu Y, et al: PAQR3 has modulatory roles in
obesity, energy metabolism, and leptin signaling. Endocrinology.
154:4525–4535. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang Y, Xie X, Li Z, Wang Z, Zhang Y,
Ling ZQ, Pan Y, Wang Z and Chen Y: Functional cooperation of RKTG
with p53 in tumorigenesis and epithelial-mesenchymal transition.
Cancer Res. 71:2959–2968. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu X, Li Z, Chan MT and Wu WK: PAQR3: A
novel tumor suppressor gene. Am J Cancer Res. 5:2562–2568.
2015.PubMed/NCBI
|
|
16
|
Wang X, Wang L, Zhu L, Pan Y, Xiao F, Liu
W, Wang Z, Guo F, Liu Y, Thomas WG, et al: PAQR3 modulates insulin
signaling by shunting phosphoinositide 3-kinase p110α to the Golgi
apparatus. Diabetes. 62:444–456. 2013. View Article : Google Scholar :
|
|
17
|
Liu C, Zhang Y, Hou Y, Shen L, Li Y, Guo
W, Xu D, Liu G, Zhao Z, Man K, et al: PAQR3 modulates H3K4
trimethylation by spatial modulation of the regulatory subunits of
COMPASS-like complexes in mammalian cells. Biochem J. 467:415–424.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Esteller M: Cancer epigenomics: DNA
methylomes and histone-modification maps. Nat Rev Genet. 8:286–298.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu Q, Zhuang K and Li H: PAQR3 plays a
suppressive role in laryngeal squamous cell carcinoma. Tumour Biol.
37:561–565. 2016. View Article : Google Scholar
|
|
21
|
Wu HG, Zhang WJ, Ding Q, Peng G, Zou ZW,
Liu T, Cao RB, Fei SJ, Li PC, Yang KY, et al: Identification of
PAQR3 as a new candidate tumor suppressor in hepatocellular
carcinoma. Oncol Rep. 32:2687–2695. 2014.PubMed/NCBI
|
|
22
|
Li Z, Ling Z-Q, Guo W, Lu XX, Pan Y, Wang
Z and Chen Y: PAQR3 expression is downregulated in human breast
cancers and correlated with HER2 expression. Oncotarget.
6:12357–12368. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fenaux P: Inhibitors of DNA methylation:
Beyond myelodys-plastic syndromes. Nat Clin Pract Oncol. 2(Suppl
1): S36–S44. 2005. View Article : Google Scholar
|
